
    
      MND-2119 is a new formulation of Icosapent. This is a phase 3 study to evaluate the efficacy
      and safety of MND-2119 compared to EPADEL CAPSULES 300 in subjects with hypertriglyceridemia.

      The study period is a total of 22 weeks and is comprised of 8 weeks run-in period, 12 weeks
      treatment period and 2 weeks follow-up period.
    
  